

study included those patients who had tested negative for hepatitis B surface antigen (HBsAg), antibody to HBsAg (anti-HBs), and antibody to hepatitis B core antigen (anti-HBc) using their first stocked blood samples, who were followed up serologically to identify new HBV incident infections among them. The other part of the study covered analysis of the relation between the frequency of incident infection and ART regimens.

## METHODS

### Patients

Since April 1997, we have stocked serum samples taken at routine clinical practice from HIV type 1 (HIV-1)-infected patients who visited the Outpatient Clinic of the AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan, under signed informed consent for use in virologic research. Every patient had been interviewed at the first visit by clinical nurse specialists at the HIV outpatient clinic using a structured questionnaire that includes items on sexuality and history of HBV vaccination. Most of the patients regularly visited our clinic every 1–3 months, and we had collected and stored their sera at almost all visits. The ethics committee of the National Center for Global Health and Medicine approved the collection and analysis of the samples. First, we selected HIV-1-infected MSM who met the following inclusion criteria: (1) the first visit to our clinic was between April 1997 and December 2009, (2) they had not received HBV vaccination before the first visit, and (3) at least 2 serum samples were available and collected at least 6 months apart. The first sample was defined as the baseline serum sample, and baseline clinical data were defined as those recorded on the date of sampling of the first stocked serum. Patients' baseline characteristics, including age, race, hepatitis C virus antibody, results of *Treponema pallidum* hemagglutination assay, and CD4<sup>+</sup> cell count were collected from the medical records.

### HBV Analysis

In order to identify new HBV incident infection, we excluded patients with previously confirmed HBV infection. The baseline samples of the patients who met the inclusion criteria described above were serologically evaluated for HBsAg, anti-HBs, and anti-HBc using ARCHITECT HBsAg QT assay, anti-HBs assay, and anti-HBc assay, respectively (Abbott Laboratories, Chicago, Illinois) [15, 16]. Patients positive for any of HBsAg, anti-HBs, and anti-HBc at baseline were excluded from the serological follow-up. The remaining patients were considered to have never been infected with HBV before the baseline. Their last stocked sample taken before or in December 2010, or before HBV vaccination if performed during the follow-up period, was analyzed for HBsAg, anti-HBs, and anti-HBc. If the last sample was negative for all 3, the patient was


considered to have never been infected with HBV up to the sampling date of the last stocked serum. If HBsAg, anti-HBs, or anti-HBc was positive in the last stocked serum, the patient was considered to have HBV incident infection during the follow-up period. In the latter case, the baseline samples were subjected to polymerase chain reaction (PCR) analysis for HBV DNA [17, 18], and all the stocked samples during the follow-up period were serologically analyzed to determine the date of HBV incident infection. The date of incident infection was defined as the sampling date of the first positive serum for any HBV serological marker. The time from the baseline to HBV incident infection was analyzed by the Kaplan-Meier method. The data were censored at the sampling date of the last stocked sample if it was negative for all analyzed HBV serological markers. Patients' age and CD4<sup>+</sup> cell count at the date of incident infection and alanine aminotransferase (ALT) values within 3 months of incident infection were collected. If an HBsAg-positive sample was available, HBV genotype and LAM-resistant mutation (rtM204V/I) were analyzed by PCR-invader assay [17–19]. The diagnosis of chronic HBV infection was considered when HBsAg was still positive in sera taken at 6 months or longer after the incident infection.

### Antiretroviral Therapy

To determine the type of ART under which HBV incident infection occurred, the regimen information of ART was collected from medical records over the period spanning from the baseline to the incidence infection or to the end of follow-up. The treatment status was divided into 4 categories: (1) No ART, no treatment with any antiretroviral agent; (2) Other-ART, ART with regimens that did not contain LAM, TDF, or emtricitabine (FTC); (3) LAM-ART, ART with LAM-containing regimens that did not contain TDF or FTC; and (4) TDF-ART, ART with TDF-containing regimens with or without LAM or FTC. Data were censored on the sampling date of the last stocked sample if it was negative for all analyzed HBV serological markers. When the treatment category was modified, the data were censored on the date of category change for the previous treatment category and a new follow-up as a different case was initiated for the replacement treatment category.

### Statistical Analysis

The time from the baseline to HBV incident infection was analyzed by the Kaplan-Meier method. The Cox proportional hazards regression analysis was used to assess the risk of HBV incident infections. The impact of patients' baseline characteristics, year of entry, the use of antiretroviral agents (any antiretroviral, and any of LAM, TDF, or FTC), and the frequency of changing ART regimen during the follow-up period was estimated with univariate analysis, and those with statistical significance were incorporated into multivariate analysis. The



**Figure 1.** Patient selection process: 1434 patients met the inclusion criteria. Of these patients, 1080 were excluded because of positive hepatitis B virus serology in the first samples. The results of various serological tests are shown. The remaining 354 were enrolled for serological follow-up. Of these, 43 were positive in the last sample analysis. Their stocked samples were analyzed serologically and the results of HBV serology using the first positive samples are indicated. Abbreviations: anti-HBc, antibody to HBV core antigen; anti-HBs, antibody to HBsAg; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; MSM, men who have sex with men.

frequency and risk of HBV incident infection during each treatment category was also assessed by univariate Cox proportional hazards regression analysis. We used hazard ratios and 95% confidence intervals to estimate the impact of each variable on incident infection. Patients' age and CD4<sup>+</sup> cell count on the date of incident infection, and peak value of ALT within 3 months of incident infection were compared between transient infection and chronic infection with Wilcoxon rank-sum test. The differences in rates of HBV genotype A and rtM204V/I mutation were compared with  $\chi^2$  test (ie, the Fisher exact test).

Statistical significance of difference was defined as a 2-sided *P* value of <.05. All statistical analyses were performed with the Statistical Package for Social Sciences version 17.0 (SPSS, Chicago, Illinois).

## RESULTS

Figure 1 shows the patient selection procedure. A total of 1434 HIV-1-infected MSM met the inclusion criteria described in the Methods section. Of these, 146 patients (10.2%) were positive for HBsAg, 737 (51.4%) were positive for anti-HBs, and 197 (13.7%) were solely positive for anti-HBc using baseline samples. The remaining 354 patients (24.7%; negative for HBsAg, anti-HBs, and anti-HBc at baseline), who were considered to have never been infected with HBV, were enrolled for serological follow-up. Table 1 lists their baseline characteristics. Serological analysis of the last sample of each of these patients showed HBV incident infection during follow-up in 43 (12.1%). Their baseline samples were found to be PCR-negative for HBV DNA, confirming that the incident infection in these patients occurred during the follow-up period. All stocked samples of the 43 patients were analyzed serologically to determine the date of HBV incident infection. HBV incident infections occurred every year between 1997 and 2010 except in 1998. The median time period from the baseline to HBV incident infection was 1.6 years (interquartile range [IQR], 192–1151 days; range, 28–4068 days). The total observation period was 1607 person-years (median, 3.7 years [IQR], 1.9–6.5 years). Figure 2 shows the Kaplan-Meier curve for the HBV incident infection for the whole cohort of enrolled patients.


In order to assess the risk of HBV incident infections, patients' baseline characteristics, year of entry, the use of any antiretroviral agents, the use of any of LAM, TDF, or FTC, and the frequency of changing ART regimen during the follow-up

**Table 1. Baseline Characteristics of the 354 Enrolled Patients**

Characteristic	Total (n = 354)	Year of Entry			
		1997–2000 (n = 61)	2001–2003 (n = 79)	2004–2006 (n = 112)	2007–2009 (n = 102)
Age, y, median (IQR)	32.0 (27.0–38.0)	32.0 (27.8–37.3)	31.0 (27.0–37.8)	32.0 (27.0–38.0)	35.0 (27.0–42.0)
Race/ethnicity					
Japanese	340 (96.0)	59 (96.7)	78 (98.7)	109 (97.3)	94 (92.2)
Asian other than Japanese	4 (1.1)	0 (0.0)	0 (0.0)	1 (0.9)	3 (2.9)
Caucasian	10 (2.8)	2 (3.3)	1 (1.3)	2 (1.8)	5 (4.9)
HCV antibody, positive	8 (2.3)	1 (1.6)	2 (2.5)	1 (0.9)	4 (3.9)
TPHA positive	101 (28.5)	23 (37.7)	20 (25.3)	30 (26.8)	28 (27.5)
CD4 <sup>+</sup> cell count, cells/mm <sup>3</sup> , median (IQR)	277 (151–404)	277 (169–417)	313 (97–443)	316 (176–413)	252 (129–359)
HIV RNA, log <sub>10</sub> copies/mL, median (IQR)	4.6 (3.8–5.2)	4.5 (3.6–5.2)	4.8 (3.9–5.4)	4.4 (3.8–4.9)	4.7 (3.9–5.2)

Data are No. (%) unless otherwise specified.

Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; TPHA, *Treponema pallidum* hemagglutination assay.



**Figure 2.** Kaplan-Meier curve showing the time to hepatitis B virus incident infection.

period were estimated using a proportional hazards model (Table 2). Younger age and higher CD4<sup>+</sup> cell count correlated positively, and use of any antiretroviral, use of LAM, TDF, or FTC, and the frequency of changing ART regimen correlated negatively with HBV incident infection, with statistical significance in univariate analysis. However, in multivariate analysis, the use of LAM, TDF, or FTC continued to show significant relation. Then, we focused on the relation between treatment status and HBV incident infection. The observation period in each patient was divided into 4 categories by treatment status: No ART, no treatment with any antiretroviral agent; Other-ART, ART with regimens that did not contain LAM, TDF, or FTC; LAM-ART, ART with LAM-containing regimens that did not contain TDF or FTC; or TDF-ART, ART with TDF-containing regimens with or without LAM or FTC. No

participant received FTC single tablet (Emtriva). All the participants who took FTC received the combination tablet of TDF/FTC (Truvada), and therefore, such treatment status was categorized as TDF-ART. The total categorized observation period of No ART, Other-ART, LAM-ART, and TDF-ART was 446, 114, 814, and 233 person-years, respectively. The number of the HBV incident infections was 30 during the No ART period, 6 during Other-ART period, 7 during LAM-ART period, and 0 during TDF-ART period. No incident infection occurred at the time of changing ART regimen. The proportional hazards model showed a significantly lower frequency of HBV incident infection during LAM- or TDF-ART (0.669 incident infections per 100 person-years) compared with that during No ART (6.726 incident infections per 100 person-years), although there was no significant difference between Other-ART (5.263 incident infections per 100 person-years) and No ART, suggesting that ART regimens with anti-HBV activity can reduce HBV incident infections by 90% (Table 3). During LAM-ART, the HIV-1 load around the period of incident infection remained below the detection limit in all the 7 infected patients, indicating excellent adherence to ART.

Figure 3 shows peak ALT levels for the 43 HBV incident infections. Among the 36 incident infections observed the No ART and Other-ART groups, 16 infections (44.4%) were asymptomatic and not associated with significant increases in ALT (peak ALT, <60 IU/L). We were able to serologically follow 33 of the 36 cases for 6 months after the date of incident infection (TDF-ART was introduced within 6 months of incident infection in the other 3 cases). Among the 33 patients, 13 (39.4%) developed chronic infection (HBsAg was still positive 6 months after the date of incident infection). The median CD4<sup>+</sup>

**Table 2. Cox Proportional Hazards Regression Analysis for the Risk of Hepatitis B Virus Incident Infection**

Factors	Univariate Analysis		Multivariate Analysis	
	Hazard Ratio (95% CI)	P Value	Hazard Ratio (95% CI)	P Value
Year of entry, per 1 y increase	.942 (.860–1.033)	.207		
Baseline characteristics				
Age, per 1 y increase	.921 (.879–.965)	.001	.958 (.917–1.001)	.054
Race (Japanese)	21.243 (.010–45 657.613)	.435		
HCV antibody	.048 (<.001–346.311)	.503		
TPHA	1.475 (.792–2.747)	.220		
CD4 <sup>+</sup> cell count, per 100 cells/mm <sup>3</sup> increase	1.121 (1.008–1.246)	.035	.882 (.752–1.034)	.121
HIV RNA, per 1 log <sub>10</sub> copies/mL increase	1.387 (.999–1.924)	.051		
Antiretroviral use during follow-up period				
Any antiretroviral	.097 (.052–.184)	<.001	.927 (.305–2.818)	.893
LAM, TDF, or FTC	.075 (.039–.146)	<.001	.110 (.031–.390)	.001
Frequency of changing regimen	.245 (.145–.414)	<.001	.700 (.385–1.270)	.240

Abbreviations: CI, confidence interval; FTC, emtricitabine; HCV, hepatitis C virus; HIV, human immunodeficiency virus; LAM, lamivudine; TDF, tenofovir disoproxil fumarate; TPHA, *Treponema pallidum* hemagglutination assay.

**Table 3. Frequency and Hazard Ratio of Hepatitis B Virus Incident Infection in Each Treatment Status Category**


ART	Observation Period (Person-Years)	Incident Infection	Hazard Ratio (95% CI)	P Value
No ART	446	30	1	
Other-ART	114	6	.924 (.381–2.239)	.861
ART containing at least 1 of LAM, TDF, and FTC <sup>a</sup>	1047	7	.113 (.049–.261)	<.001
LAM-ART	814	7		
TDF-ART	233	0		

Abbreviations: ART, antiretroviral therapy; CI, confidence interval; FTC, emtricitabine; LAM, lamivudine; TDF, tenofovir disoproxil fumarate; LAM-ART, ART with LAM-containing regimens that did not contain TDF or FTC; Other-ART, ART with regimens that did not contain LAM, TDF, or FTC; TDF-ART, ART with TDF-containing regimens with or without LAM or FTC.

<sup>a</sup> No participant received FTC single tablet (Emtriva) during the observation period. All the participants who took FTC received the combination tablet of TDF/FTC (Truvada), and therefore, such treatment status was categorized into TDF-ART.

cell count was lower in the patients who developed chronic infection than in those with transient infection, although the difference was not significant ( $P = .068$ ; Table 4), indicating that HIV-related immunodeficiency may play a role in the induction of chronic HBV infection. Among the 7 incident infections observed during LAM-ART, only 2 patients (28.6%) were symptomatic, had significant rise in ALT, and developed chronic HBV infection, and both of these infections were caused by LAM-resistant HBV (Table 5). The other 5 cases were asymptomatic and transient. Three of them were caused by LAM-sensitive strains and 1 was by LAM-resistant strain. HBsAg-positive serum sample was not available in the last case. LAM-resistant HBV was more frequently identified in analyzed incident infections during LAM-containing ART (50.0%) than in those during no ART and other ART (7.1%) ( $P = .029$ ). Considered together, LAM seems to prevent acquisition of HBV infection, progression to symptomatic hepatitis, and development of chronic infection even after the development of infection, although these effects may be less pronounced in patients with LAM-resistant strains.

Among the 43 infection cases observed during total serological follow-up, HBsAg-positive samples were available in 34 cases and their HBV genotype was determined. Genotype A was the most frequent, as reported previously [10, 20–22], and genotypes B, G, and H were also identified. The rate of development of chronic infection was higher in genotype A than in other genotypes as previously reported [23], although the difference was not significant in our study. In the remaining 9 cases, only anti-HBc with (7 cases) or without (2 cases) anti-HBs were detected, although their samples were available and



**Figure 3.** Peak alanine aminotransferase (ALT) values in hepatitis B virus (HBV) incident infections according to treatment regimen. Thirty, 6, and 7 HBV incident infections were observed during No antiretroviral therapy (ART), Other-ART, and lamivudine (LAM)–ART, respectively. No incident infection was identified during tenofovir disoproxil fumarate (TDF)–ART. No participant received emtricitabine (FTC) single tablet (Emtriva) during the observation period. All the participants who took FTC received the combination tablet of TDF/FTC (Truvada), and therefore, such treatment status was categorized into TDF-ART. Data are peak ALT values measured within 3 months of the date of incident infections. LAM-resistant mutation (rtM204V/I) was analyzed in 34 cases using the available hepatitis B surface antigen (HBsAg)–positive samples. Open squares: patients infected with LAM-resistant HBV. Closed circles and squares: patients who developed chronic infection (HBsAg-positive 6 months after the date of incident infection). Checked circles and squares: patients who received TDF-containing ART within 6 months of incident infection. Abbreviations: ALT, alanine aminotransferase; ART, antiretroviral therapy; LAM, lamivudine.

serologically analyzed at least every 3 months around the incident infection.

## DISCUSSION

The results of this serological follow-up study indicated that LAM- and TDF-containing ART regimens protect against HBV incident infection. Furthermore, the results also suggested that LAM prevents progression to symptomatic hepatitis and development of chronic infection even after the development of HBV incident infection, provided such infection is caused by LAM-sensitive strains. However, it seems that LAM-resistant strains may evade this protective effect. One previous study that estimated the incidence of acute HBV infection among HIV-infected patients reported similar frequencies in patients receiving ART with and without LAM [5]. However, the authors defined immunoglobulin M anti-HBs positivity as a marker of HBV incident infection and did not exclude anti-HBc–positive patients at study entry. This probably made it difficult to distinguish incident infection from reactivation of chronic infection, as discussed in the report. In this study, we identified a

**Table 4. Patient Characteristics and Clinical Features of Hepatitis B Virus Incident Infections in the No Antiretroviral Therapy (ART) and Other-ART Treatment Categories**

Factors	Transient (n = 20)	Chronic <sup>a</sup> (n = 13)	Treated <sup>b</sup> (n = 3)	P Value <sup>c</sup>
Age, y, median (IQR)	31.0 (28.0–33.0)	29.0 (25.0–38.3)	25.0 (21.0–35.0) <sup>d</sup>	.406
CD4 <sup>+</sup> cell count, cells/mm <sup>3</sup> , median (IQR)	371 (308–518)	320 (235–383)	674 (206–1935) <sup>d</sup>	.068
Peak ALT level <sup>e</sup> , U/L, median (IQR)	65 (30–573)	264 (115–774)	31 (15–314) <sup>d</sup>	.162
HBV genotype, No. (%)				.645
Genotype A	9 (45.0)	11 (84.6)	2 (66.7)	
Other genotypes	3 (15.0)	2 (15.4)	1 (33.3)	
Genotype unknown	8 (40.0)	0 (0.0)	0 (0.0)	
HBV rtM204V/I mutation, No. (%)				.480
Positive	1 (5.0)	0 (0.0)	1 (33.3)	
Negative	11 (55.0)	13 (100.0)	2 (66.7)	
Unknown	8 (40.0)	0 (0.0)	0 (0.0)	

Abbreviations: ALT, alanine aminotransferase; HBV, hepatitis B virus; IQR, interquartile range.

<sup>a</sup> Hepatitis B surface antigen–positive 6 months after the date of incident infection.

<sup>b</sup> Treated cases with tenofovir disoproxil fumarate–containing antiretroviral therapy within 6 months of incident infection.

<sup>c</sup> P values between transient and chronic cases calculated with Wilcoxon rank-sum tests for continuous variables and  $\chi^2$  tests for proportions.

<sup>d</sup> Minimum and maximum values.

<sup>e</sup> Peak ALT level within 3 months of incident infection.

significant number of isolated anti-HBc–positive patients, a finding in agreement with previous reports [24–27], and

**Table 5. Patient Characteristics and Clinical Features of Hepatitis B Virus Incident Infections During LAM-ART Treatment**

Factors	Transient (n = 5)	Chronic <sup>a</sup> (n = 2)	P Value <sup>b</sup>
Age, y, median (IQR)	33.0 (30.3–36.5)	38.0 (33.0–43.0) <sup>c</sup>	.329
CD4 <sup>+</sup> cell count, cells/mm <sup>3</sup> , median (IQR)	430 (267–648)	362 (360–364) <sup>c</sup>	.699
Peak ALT level <sup>d</sup> , U/L, median (IQR)	22 (14–51)	1133 (941–1325) <sup>c</sup>	.051
HBV genotype, No. (%)			>.999
Genotype A	3 (60.0)	1 (50.0)	
Other genotypes	1 (20.0)	1 (50.0)	
Genotype unknown	1 (20.0)	0 (0.0)	
HBV rtM204V/I mutation, No. (%)			.400
Positive	1 (20.0)	2 (100.0)	
Negative	3 (60.0)	0 (0.0)	
Unknown	1 (20.0)	0 (0.0)	

Abbreviations: ALT, alanine aminotransferase; HBV, hepatitis B virus; IQR, interquartile range; LAM-ART, ART with LAM-containing regimens that did not contain TDF or FTC.

<sup>a</sup> Hepatitis B surface antigen–positive 6 months after the date of incident infection.

<sup>b</sup> P values calculated with Wilcoxon rank-sum tests for continuous variables and  $\chi^2$  tests for proportions.

<sup>c</sup> Minimum and maximum values.

<sup>d</sup> Peak ALT level within 3 months of incident infection.

excluded them from the serological follow-up to avoid improper inclusion of isolated anti-HBc–positive ones as HBV-naïve [28, 29].

HBV vaccination is recommended for individuals seeking evaluation or treatment for sexually transmitted diseases, HIV-infected patients, sexually active persons with >1 partner, and MSM [13]. However, the response and durability of adequate titers of anti-HBs are often reduced in HIV-infected patients [30–34]. Modified regimens of vaccination have been reported to improve anti-HBs response in HIV-infected patients, although the response rate was still low in those with low CD4<sup>+</sup> cell counts [35–37]. Our study demonstrated the HBV prophylactic effects of LAM- and TDF-containing ART regimens, suggesting that ART should be initiated before HBV vaccination, especially in those with low CD4<sup>+</sup> cell counts. Early introduction of ART was recommended recently not only for HIV-infected individuals, but also for prevention of transmission to others [38, 39]. Early introduction of treatment may also be recommended to prevent HBV infection to the patients themselves if they are HBV-naïve. One randomized clinical trial reported the prophylactic effect of TDF combined with FTC in HIV prevention in seronegative MSM [40]. However, in that trial, HBV vaccination was offered to all susceptible participants, which made it impossible to estimate the prophylactic effect of the treatment on HBV prevention.

Our study carries certain limitations related to its retrospective nature. Patients on ART might have more opportunities to improve their behavior to prevent transmission of HIV to others, which could reduce HBV infection in themselves but

introduce bias in our analysis. However, the results suggest prophylaxis against potential HBV infection by oral medications, which could be useful for nonimmunized medical care providers.

## Notes

**Acknowledgments.** We thank Y. Takahashi and F. Negishi for the helpful assistance in sample processing, and A. Nakano for the excellent project coordination. We also thank all physicians and nurses at the AIDS Clinical Center, National Center for Global Health and Medicine, for the dedicated clinical practice and patient care.

**Financial support.** This work was supported in part by Grants-in Aid for AIDS research from the Ministry of Health, Labor, and Welfare (H23-AIDS-001), and the Global COE Program (Global Education and Research Center Aiming at the Control of AIDS), MEXT, Japan.

**Potential conflicts of interest.** H. G. has received honoraria from MSD K.K., Abbott Japan, Janssen Pharmaceutical K.K., Torii Pharmaceutical, and ViiV Healthcare. S. O. has received honoraria and research funding from MSD K.K., Abbott Japan, Janssen Pharmaceutical K.K., Pfizer, Roche Diagnostics K.K., and ViiV Healthcare, and has received honoraria from Astellas Pharmaceutical K.K., Bristol-Myers K.K., Daiichisankyo, Dainippon Sumitomo Pharma, GlaxoSmithKline, K.K., Taisho Toyama Pharmaceutical, and Torii Pharmaceutical. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

## References

- Colin JF, Cazals-Hatem D, Lioriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. *Hepatology* **1999**; *29*:1306–10.
- Lacombe K, Bottero J, Lemoine M, et al. HIV/hepatitis B virus coinfection: current challenges and new strategies. *J Antimicrob Chemother* **2010**; *65*:10–7.
- Soriano V, Vispo E, Labarga P, et al. Viral hepatitis and HIV coinfection. *Antiviral Res* **2010**; *85*:303–15.
- Kourtis AP, Bulterys M, Hu DJ, et al. HIB-HBV coinfection—a global challenge. *N Engl J Med* **2012**; *366*:1749–52.
- Kellerman SE, Hanson DL, McNaghten AD, et al. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. *J Infect Dis* **2003**; *188*:571–7.
- Lincoln D, Petoumenos K, Dore GJ, et al. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. *HIV Med* **2003**; *4*:241–9.
- Nunez M, Soriano V. Management of hepatitis co-infected with hepatitis B virus and HIV. *Lancet Infect Dis* **2005**; *6*:374–82.
- Koziel MJ, Peters MG. Viral hepatitis in HIV infection. *N Engl J Med* **2007**; *356*:1445–54.
- Hattori J, Shiino T, Gatanaga H, et al. Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. *Antiviral Res* **2010**; *88*:72–9.
- Fujisaki S, Yokomaku Y, Shiino T, et al. Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfecting with HIV-1 in Japan. *J Clin Microbiol* **2011**; *49*:1017–24.
- Thio CL, Seaberg EC, Skolasky RL, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). *Lancet* **2002**; *360*:1921–6.
- Thio CL. Hepatitis B and human immunodeficiency virus coinfection. *Hepatology* **2009**; *49*:S138–45.
- Brook G, Main J, Nelson M, et al. British HIV association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus **2010**. *HIV Med* **2010**; *11*:1–30.
- Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International AIDS Society–USA panel. *JAMA* **2012**; *308*:387–402.
- Kinn S, Akhavan S, Agut H, et al. Performance of the DiaSorin LIAISON anti-HBs II for the detection of hepatitis B surface antibodies: comparison with the Abbott ARCHITECT anti-HBs assay. *J Clin Virol* **2011**; *50*:297–302.
- Ollier L, Laffont C, Kechekjian A, et al. Detection of antibodies to hepatitis B core antigen using the Abbott ARCHITECT anti-HBc assay: analysis of borderline reactive sera. *J Virol Methods* **2008**; *154*:206–9.
- Tadokoro K, Kobayashi M, Yamaguchi T, et al. Classification of hepatitis B virus genotypes by the PCR-invader method with genotype-specific probes. *J Virol Methods* **2006**; *138*:30–9.
- Tadokoro K, Suzuki F, Kobayashi M, et al. Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay. *J Virol Methods* **2011**; *171*:67–73.
- Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. *Gastroenterology* **2009**; *137*:1593–608.
- Koibuchi T, Hitani A, Nakamura T, et al. Predominance of genotype A HBV in an HBV-HIV-1 dually positive population compared with an HIV-1-negative counterpart in Japan. *J Med Virol* **2001**; *64*:435–40.
- Matsuura K, Tanaka Y, Hige S, et al. Distribution of hepatitis B virus genotypes with chronic infection in Japan shifting toward an increase of genotype A. *J Clin Microbiol* **2009**; *47*:1476–83.
- Kobayashi M, Ikeda K, Arase Y, et al. Change of hepatitis B virus genotypes in acute and chronic infections in Japan. *J Med Virol* **2008**; *80*:1880–4.
- Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. *J Gastroenterol Hepatol* **2011**; *26*:S123–30.
- Gandhi RT, Wurcel A, Lee H, et al. Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. *Clin Infect Dis* **2003**; *36*:1602–5.
- French AL, Operskalski E, Peters M, et al. Isolated hepatitis B core antibody is associated with HIV and ongoing but not resolved hepatitis C virus infection in a cohort of US women. *J Infect Dis* **2007**; *195*:1437–42.
- Perez-Rodriguez MT, Sopena B, Crespo M, et al. Clinical significance of “anti-HBc alone” in human immunodeficiency virus-positive patients. *World J Gastroenterol* **2009**; *15*:1237–41.
- Koo YX, Tan DS, Tan IB, et al. “Anti-HBc alone” in human immunodeficiency virus-positive and immune-suppressed lymphoma patients. *World J Gastroenterol* **2009**; *15*:3834–5.
- Gandhi RT, Wurcel A, Lee H, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. *J Infect Dis* **2005**; *191*:1435–41.
- French AL, Lin MY, Evans CT, et al. Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women. *Clin Infect Dis* **2009**; *49*:148–54.
- Biggar RJ, Goedert JJ, Hoofnagle J. Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV. *N Engl J Med* **1987**; *316*:630–1.
- Collier AC, Corey L, Murphy VL, et al. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. *Ann Intern Med* **1988**; *109*:101–5.
- Loke RH, Murray-Lyon IM, Coleman JC, et al. Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: an indicator of poor prognosis. *J Med Virol* **1990**; *31*:109–11.
- Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. *AIDS* **1994**; *8*:558–9.
- del Pozo Balado Mdel M, Leal M, Mendez Lagares G, et al. Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. *J Infect Dis* **2010**; *202*:362–9.
- Fonseca MO, Pang LW, de Paula Cavalheiro N, et al. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult

- patients comparing a standard dose to a double dose. *Vaccine* **2005**; 23: 2902–8.
36. Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis vaccine regimen in adults with HIV-1: a randomized controlled trial. *JAMA* **2011**; 305:1432–40.
  37. Flynn PM, Cunningham CK, Rudy B, et al. Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. *J Acquir Immune Defic Syndr* **2011**; 56:325–32.
  38. Wilson DP, Law MG, Grulich AE, et al. Relation between HIV viral load and infectiousness: a model-based analysis. *Lancet* **2008**; 372: 314–20.
  39. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med* **2011**; 365: 493–505.
  40. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med* **2010**; 363:2587–99.

# Assessment of Antigenemia Assay for the Diagnosis of Cytomegalovirus Gastrointestinal Diseases in HIV-Infected Patients

Yohei Hamada, MD,<sup>1</sup> Naoyoshi Nagata, MD,<sup>2</sup> Takuro Shimbo, MD, PhD,<sup>3</sup> Toru Igari, MD,<sup>4</sup> Ryo Nakashima, MD,<sup>2</sup> Naoki Asayama, MD,<sup>2</sup> So Nishimura, MD,<sup>2</sup> Hirohisa Yazaki, MD, PhD,<sup>1</sup> Katsuji Teruya, MD, PhD,<sup>1</sup> Hiroyuki Gatanaga, MD, PhD,<sup>1,5</sup> Yoshimi Kikuchi, MD, PhD,<sup>1</sup> Junichi Akiyama, MD,<sup>2</sup> Norio Ohmagari, MD,<sup>6</sup> Naomi Uemura, MD, PhD,<sup>7</sup> and Shinichi Oka, MD, PhD<sup>1,5</sup>

## Abstract

We conducted a single-center prospective study to evaluate the utility of cytomegalovirus (CMV) antigenemia assay for the diagnosis of CMV-gastrointestinal disease (GID). The study subjects were HIV-infected patients with CD4 count  $\leq 200 \mu\text{L}/\text{cells}$  who had undergone endoscopy. A definite diagnosis of CMV-GID was made by histological examination of endoscopic biopsied specimen. CMV antigenemia assay (C10/C11 monoclonal antibodies), CD4 count, HIV viral load, history of HAART, and gastrointestinal symptoms as measured by 7-point Likert scale, were assessed on the same day of endoscopy. One hundred cases were selected for analysis, which were derived from 110 cases assessed as at high-risk for CMV-GID after endoscopy screening of 423 patients. Twelve patients were diagnosed with CMV-GID. Among the gastrointestinal symptoms, mean bloody stool score was significantly higher in patients with CMV-GID than in those without (2.5 vs. 1.7,  $p=0.02$ ). The area under the receiver-operating characteristic curve of antigenemia was 0.80 (95%CI 0.64–0.96). The sensitivity, specificity, positive likelihood ratio (LR), and negative LR of antigenemia were 75.0%, 79.5%, 3.7, and 0.31, respectively, when the cutoff value for antigenemia was  $\geq 1$  positive cell per 300,000 granulocytes, and 50%, 92.0%, 5.5, and 0.55, respectively, for  $\geq 5$  positive cells per 300,000 granulocytes. In conclusion, CMV antigenemia seems a useful diagnostic test for CMV-GID in patients with HIV infection. The use of  $\geq 5$  positive cells per 300,000 granulocytes as a cutoff value was associated with high specificity and high positive LR. Thus, a positive antigenemia assay with positive endoscopic findings should allow the diagnosis of CMV-GID without biopsy.

## Introduction

CYTOMEGALOVIRUS (CMV) IS A MAJOR opportunistic pathogen of gastrointestinal diseases in patients with HIV infection. The incidence of CMV end-organ diseases, including CMV gastrointestinal disease (CMV-GID), has declined significantly following the introduction of highly active antiretroviral therapy (HAART). However, CMV-GID remains an important cause of morbidity and mortality because it can result in massive bleeding and gastrointestinal perforation.<sup>1–5</sup> There-

fore, diagnosis at an early stage is essential.<sup>6</sup> Tissue biopsy is invasive and carries the risk of hemorrhage or perforation. Instead, endoscopy with biopsy provides definitive diagnosis.

The CMV blood antigenemia assay is a noninvasive method to detect CMV viremia and its utility has been evaluated previously for the diagnosis of CMV end-organ diseases in patients with HIV infection.<sup>7–10</sup> However, many of those studies included various types of CMV end-organ diseases such as CMV retinitis and pneumonia. To our knowledge, there are no studies that have investigated the value of

<sup>1</sup>AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.  
Departments of <sup>2</sup>Gastroenterology and Hepatology, <sup>3</sup>Clinical Research and Informatics, International Clinical Research Center Research Institute, <sup>4</sup>Pathology Division of Clinical Laboratory, <sup>5</sup>Division of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health, Tokyo, Japan.

<sup>5</sup>Center for AIDS Research, Kumamoto University, Kumamoto, Japan.

<sup>7</sup>Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Kohnodai Hospital, Chiba, Japan.



CMV antigenemia assay in the diagnosis of CMV-GID, especially in HIV-infected patients.

We conducted a prospective study to assess the utility of the CMV antigenemia assay for the diagnosis of CMV-GID in patients with HIV infection.

## Methods

### Subjects

We prospectively recruited 423 HIV-infected patients who had undergone endoscopy between 2009 and 2012 at the National Center for Global Health and Medicine (NCGM), a 900-bed hospital located in the Tokyo metropolitan area and the largest referral center for HIV/AIDS in Japan. These patients were generally referred for endoscopy by the attending physician, based on the presence of gastrointestinal symptoms or for asymptomatic screening. Patients with CD4 count  $\leq 200$  were included in the analysis. We excluded patients who had received endoscopy for follow-up evaluation less than 3 months after treatment of gastrointestinal disease, who were under treatment for other CMV end-organ diseases, and those who were free of antigenemia.

The institutional review board of our hospital approved this study (approval No. 715).

### Clinical factors

Gastrointestinal (GI) symptoms, CD4 count, HIV-RNA, history of HAART, and sexual behavior were collected before endoscopy. To evaluate GI symptoms, the modified gastrointestinal symptom rating scale (GSRS) rating on a 7-graded Likert scale was used.<sup>11,12</sup> The modified GSRS consists of the original GSRS (abdominal pain, heart burn, acid regurgitation, sucking sensation in the epigastrium, nausea and vomiting, borborygmi, abdominal distention, eructation, increased flatus, decreased passage of stools, loose stools, hard stools, urgent need for defecation, feeling of incomplete evacuation), plus odynophagia, chronic diarrhea, and bloody stool. Chronic diarrhea was defined as an episode lasting longer than 4 weeks.

### Antigenemia assay

Antigenemia assay using C10/C11 monoclonal antibodies (Mitsubishi Chemical Medience, Tokyo, Japan) was performed as described previously.<sup>13-15</sup> A positive result of the CMV antigenemia assay was defined as  $\geq 1$  CMV-positive cell per 300,000 granulocytes applied. The assay was performed on the same day of endoscopy. For patients who were empirically prescribed anti-CMV therapy before endoscopy, CMV antigenemia obtained before initiating the therapy was used for analysis.

### Diagnosis of CMV-GID

CMV-GID was suspected based on endoscopic findings, such as patchy erythema, edematous mucosa, multiple erosions, and ulcers.<sup>16,17</sup> Biopsy was performed when such endoscopic findings were encountered. CMV-GID was defined as the detection of large cells with intranuclear inclusions, alone, or in association with granular cytoplasmic inclusions on histological examination of biopsy specimens.<sup>1</sup> Biopsy sections were stained with hematoxylin and eosin, and also

immunohistochemically stained with anti-CMV. The results were considered positive when the above-mentioned cells showed marked brown coloration in both nuclei and cytoplasm.

### Statistical analysis

We divided patients into two groups based on the presence or absence of CMV-GID. Patient characteristics and clinical findings were then compared in the two groups using the Mann-Whitney *U* test,  $\chi^2$  test, and Fisher's exact test for quantitative and qualitative variables, respectively. Area under the receiver-operating characteristic curve (ROC-AUC) analysis was used to quantify the accuracy of CMV antigenemia assay. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), positive likelihood ratio (LR), negative LR, and diagnostic odds ratio for the diagnosis of CMV-GID were also calculated for different cutoff values ( $\geq 1$  positive cells per 300,000 granulocytes and  $\geq 5$  positive cells per 300,000 granulocytes). In a subgroup analysis stratified by patients with and without history of HAART, the sensitivity, specificity, PPV, and NPV were calculated using the cutoff value of CMV-positive cells of  $\geq 1$  per 300,000 granulocytes. All statistical analyses were performed using Stata software (version 10, Stata Co., USA).


## Results

A total of 100 patients were selected for analysis after the application of the aforementioned exclusion criteria (Fig. 1). The majority of patients were males, and the median age was 40. The median CD4 count was 84 [interquartile range (IQR) 33.3–148.8] and 58.0% of the patients had history of HAART. Twelve patients were diagnosed with CMV-GID based on the abovementioned criteria (Fig. 2). In these patients, the median CMV antigenemia value was 4 positive cells per 300,000 granulocytes (range, 0–786). CMV-GID was localized to the upper GI tract in one patient, in the lower GI tract in 11, and in both parts in two.

Table 1 shows the baseline and demographic characteristics of the participating patients. Univariate analysis showed that significantly fewer patients with CMV-GID had history of HAART than those without CMV-GID ( $p=0.016$ ) and median CD4 count was not significantly different between the two groups ( $p=0.356$ ). The number of patients with positive CMV antigenemia was significantly higher in those with CMV-GID than those without ( $p<0.01$ ). The mean bloody stool scores was significantly higher in patients with CMV-GID than in those without CMV-GID ( $p=0.021$ ). In addition, there was a trend toward higher scores for heartburn ( $p=0.064$ ) and chronic diarrhea ( $p=0.078$ ) in patients with CMV-GID. The proportions of patients with the other symptoms were not different between the two groups.

ROC-AUC of the CMV antigenemia assay was 0.80 (95%CI 0.64–0.96). Table 2 lists the data that describe the diagnostic accuracy of CMV antigenemia assay. Using a cutoff value of  $\geq 1$  positive cell per 300,000 granulocytes for positive CMV antigenemia assay, the sensitivity, specificity, positive LR, and negative LR of antigenemia for CMV-GID were 75.0%, 79.5%, 3.7, and 0.31, respectively. The use of a cutoff value of  $\geq 5$  positive cells per 300,000 granulocytes yielded 50.0% sensitivity, 90.9% specificity, a positive LR of 5.5, and negative LR of 0.55 for the diagnosis of CMV-GID. Subgroup analysis

FIG. 1. Flow diagram of patient selection. CMV, cytomegalovirus; EOD, end-organ disease; GID, gastrointestinal disease.



showed a sensitivity of 66.7% and specificity of 83.6% for the assay for patients with history of HAART, while higher sensitivity (77.8%) and lower specificity (72.7%) were noted for those without ART.

**Discussion**

The present study provides the first prospective analysis of the CMV antigenemia assay in the diagnosis of CMV-GID in HIV-infected patients with 75.0% sensitivity and 79.5% specificity. The antigenemia assay is one of the most widely used methods for detecting reactivation of CMV infection, but only a few studies have examined its diagnostic value for CMV-GID,<sup>18-21</sup> and all were retrospective in design. Jang et al.<sup>20</sup> recently reported that the sensitivity and specificity of

the CMV antigenemia assay for the diagnosis of CMV-GID were 54% and 88%, respectively, in patients with secondary immunodeficiency disease. Nagata et al.<sup>21</sup> also reported 65.4% sensitivity and 93.6% specificity of the CMV antigenemia assay for CMV-GID in patients with positive endoscopic findings. The present study demonstrated higher sensitivity (75.0%) and lower specificity (79.5%) than those studies. This difference in accuracy could be explained by the difference in the study population since only HIV-infected patients were included in our study, whereas previous studies included a substantial number of patients with immune deficiency due to etiologies other than HIV infection.

The sensitivity of antigenemia assay for the diagnosis of CMV end-organ disease in HIV-infected patients reported in previous studies was generally higher than that in the present

FIG. 2. Endoscopic and pathological features in representative cases. (A) Large distinct ulcer in the sigmoid colon; (B) Ulcer was more clearly observed with indigo carmine; (C) Large cells with intranuclear inclusions or associated with granular cytoplasmic inclusions (hematoxylin and eosin staining); (D) Cytomegalovirus (CMV)-infected cells (arrows) show brown coloration in both nuclei and cytoplasm (immunohistochemical staining with anti-CMV). (Color image can be found at [www.liebertonline.com/apc](http://www.liebertonline.com/apc).)




TABLE 1. CLINICAL CHARACTERISTICS OF PATIENTS WITH AND WITHOUT CMV-GID

	CMV-GID (n=12)	Non CMV-GID (n=88)	p Value
Age (IQR)	39 (36–46)	40 (37–51)	0.451
Male gender (%)	11 (91.7)	87 (98.9)	0.227
CD4 count (/μL) (IQR)	68.5 (28.8–123.3)	84 (38.3–151.0)	0.356
HIV viral load (log <sub>10</sub> /mL) (IQR)	4.58 (3.27–5.24)	2.84 (1.60–5.08)	0.084
History of HARRT (%)	3 (5.2)	55 (62.5)	0.016
MSM (%)	9 (75.0)	69 (78.4)	0.723
Positive CMV antigenemia (%)	9 (75.0)	18 (20.5)	<0.001
Epigastric pain (SD)	2.5 (2.1)	1.8 (1.3)	0.373
Heartburn (SD)	2.5 (1.5)	1.8 (1.3)	0.064
Nausea and vomiting (SD)	2.4 (1.7)	2.0 (1.5)	0.384
Odynophagia (SD)	2.1 (1.7)	1.7 (1.5)	0.481
Chronic diarrhea (SD)	2.3 (1.3)	1.8 (1.4)	0.078
Bloody stool (SD)	2.5 (2.0)	1.7 (1.5)	0.021

CD4 cell counts within 1 week and HIV-RNA viral load within 1 month were checked at the day of endoscopy. A positive result for real-time HIV RNA was defined as  $\geq 40$  copies/mL. History of HAART was collected from the medical records prior to endoscopy. Sexual behavior was defined as men who have sex with men (MSM) or heterosexual.

CMV, cytomegalovirus; GID, gastrointestinal disease; HAART, highly active antiretroviral therapy; IQR, interquartile range; MSM, men who have sex with men; SD, standard deviation.

study.<sup>8–10,22–26</sup> This difference could be explained by the fact that the current study focused on gastrointestinal disease, while previous studies included various CMV diseases such as retinitis, cholangitis, pneumonia, and encephalitis.<sup>8–10,22–26</sup> The diagnostic accuracy of CMV antigenemia may vary depending on the site and extent of organ/tissue involvement.

Identification of CMV cells in tissue samples obtained by endoscopic biopsy is considered the gold standard for the diagnosis of CMV-GID.<sup>1,2,6</sup> The endoscopic findings in CMV-GID include ulcer and mucosal inflammation;<sup>16,17</sup> however, physicians may not consider it necessary to take a biopsy in patients with only mucosal inflammation without ulceration. Even in cases of severe deep or bleeding ulcers, some physicians may hesitate to perform a biopsy. In such cases, no definite diagnosis of CMV-GID can be made. Our results suggest that the CMV antigenemia assay is to some extent useful for the diagnosis of CMV-GID in patients with endoscopic findings, especially when CMV positive cell counts are high. Considering the high specificity and high positive LR (5.5) of the positive CMV cell count  $\geq 5$ , the use of this method before endoscopy could potentially avoid complications due to biopsy.

One limitation of this study was the single-center nature of the investigation. Significant differences in independent factors were not detected in the present study probably due to the small number of patients with CMV-GID. For example, we used gastrointestinal symptoms with score of 7 points on the Likert scale, but the differences in most symptoms between patients with or without CMV-GID did not reach statistical significance due to the small number of cases. Further studies based on larger population are needed. Another limitation is a selection bias related to the selection criteria applied in the present study: only patients who underwent endoscopy for such reasons as symptoms and screening were included in the study.

In conclusion, the CMV antigenemia assay showed relatively good sensitivity and specificity for the diagnosis of CMV-GID in patients with HIV infection. Furthermore, specificity and positive LR improved when the cutoff value of CMV cell count was increased from 1 to  $\geq 5$  positive cells per 300,000 granulocytes. Considering the high specificity of the test, the use of this method before endoscopy could potentially avoid complications due to biopsy.

TABLE 2. DIAGNOSTIC ACCURACY OF CMV ANTIGENEMIA ASSAY FOR CMV-GID USING DIFFERENT CUTOFF VALUES AND HISTORY OF HAART

	Sensitivity (95%CI)	Specificity (95%CI)	PPV (95%CI)	NPV (95%CI)	LR+ (95%CI)	LR- (95%CI)	OR (95%CI)
CMV antigenemia $\geq 1$ positive cell	75.0% (42.8–94.5)	79.5% (69.6–87.4)	33.3% (16.5–54.0)	95.9% (8.5–99.1)	3.7 (2.2–6.2)	0.31 (0.11–0.84)	11.7 (3.1–44)
CMV antigenemia $\geq 5$ positive cells	50.0% (21.1–78.9)	90.9% (82.9–96.0)	42.9% (17.7–71.1)	93% (85.4–97.4)	5.5 (2.3–13.1)	0.55 (0.31–0.97)	10.0 (2.7–37.1)
History of HAART							
Yes <sup>a</sup>	66.7% (9.4–99.2)	83.6% (71.2–92.2)	18.2% (2.3–51.8)	97.9% (88.7–99.9)	3.7 (2.2–6.2)	0.31 (0.11–0.84)	10.2 (1.2–NA)
No <sup>a</sup>	77.8% (40.0–97.2)	72.7% (54.5–86.7)	43.8% (19.8–70.1)	92.3% (74.9–99.1)	2.9 (1.5–5.5)	0.31 (0.88–1.1)	9.33 (1.79–NA)

<sup>a</sup>Cutoff value of  $\geq 1$  positive cell per 300,000 granulocytes was used in the analysis.

CMV, cytomegalovirus; HAART, highly active antiretroviral therapy; LR+, positive likelihood ratio; LR-, negative likelihood ratio; NPV, negative predictive value; OR, odds ratio; PPV, positive predictive value.

### Acknowledgments

We are grateful to Hisae Kawashiro (Clinical Research Coordinator) for help with data collection. The authors thank all other clinical staff at the AIDS Clinical Center and all the staff of the endoscopy unit.

This work was supported by Grants-in Aid for AIDS research from the Japanese Ministry of Health, Labor, and Welfare (H23-AIDS-001), and the Global Center of Excellence Program (Global Education and Research Center Aiming at the Control of AIDS) from the Japanese Ministry of Education, Science, Sports and Culture.

### Author Disclosure Statement

The other authors declare no conflict of interest.

### References

- Goodgame RW. Gastrointestinal cytomegalovirus disease. *Ann Intern Med* 1993;119:924-935.
- Baroco AL, Oldfield EC. Gastrointestinal cytomegalovirus disease in the immunocompromised patient. *Curr Gastroenterol Rep* 2008;10:409-416.
- Toogood GJ, Gillespie PH, Gujral S, et al. Cytomegalovirus infection and colonic perforation in renal transplant patients. *Transpl Int* 1996;9:248-251.
- Almeida N, Romaozinho JM, Amaro P, Ferreira M, Cipriano MA, Leitao MC. Fatal mid-gastrointestinal bleeding by cytomegalovirus enteritis in an immunocompetent patient. *Acta Gastroenterol Belg* 2009;72:245-248.
- Frank D, Raicht RF. Intestinal perforation associated with cytomegalovirus infection in patients with acquired immune deficiency syndrome. *Am J Gastroenterol* 1984;79:201-205.
- Korkmaz M, Kunefeci G, Selcuk H, et al. The role of early colonoscopy in CMV colitis of transplant recipients. *Transplant Proc* 2005;37:3059-3060.
- Skiest DJ, Crosby C. CMV pp65 antigen testing is of limited utility in the diagnosis of concomitant CMV disease in HIV-infected patients in the HAART era. *J Clin Virol* 2003;28:203-213.
- Podzamczar D, Ferrer E, Garcia A, et al. pp65 antigenemia as a marker of future CMV disease and mortality in HIV-infected patients. *Scand J Infect Dis* 1997;29:223-227.
- Bek B, Boeckh M, Lepenies J, et al. High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenemia assay for diagnosis of CMV disease in AIDS patients and follow-up. *J Clin Microbiol* 1996;34:457-459.
- Wattanamano P, Clayton JL, Kopicko JJ, et al. Comparison of three assays for cytomegalovirus detection in AIDS patients at risk for retinitis. *J Clin Microbiol* 2000;38:727-732.
- Svedlund J, Sjodin I, Dotevall G. GSRS—A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. *Dig Dis Sci* 1988;33:129-134.
- Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. *Qual Life Res* 1998;7:75-83.
- Gondo H, Minematsu T, Harada M, et al. Cytomegalovirus (CMV) antigenemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. *Br J Haematol* 1994;86:130-137.
- Kanda Y, Mineishi S, Saito T, et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan. *Bone Marrow Transplant* 2001;27:437-444.
- Mori T, Okamoto S, Matsuoka S, et al. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation. *Bone Marrow Transplant* 2000;25:765-769.
- Rene E, Marche C, Chevalier T, et al. Cytomegalovirus colitis in patients with acquired immunodeficiency syndrome. *Dig Dis Sci* 1988;33:741-750.
- Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. *Clin Infect Dis* 2002;34:1094-1097.
- Mori T, Mori S, Kanda Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2004;33:431-434.
- Fica A, Cervera C, Perez N, et al. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: Clinical features and usefulness of conventional diagnostic tests. *Transpl Infect Dis* 2007;9:203-210.
- Jang EY, Park SY, Lee EJ, et al. Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. *Clin Infect Dis* 2009;48:e121-124.
- Nagata N, Kobayakawa M, Shimbo T, et al. Diagnostic value of antigenemia assay for cytomegalovirus gastrointestinal disease in immunocompromised patients. *World J Gastroenterol* 2011;17:1185-1191.
- Pannuti CS, Kallas EG, Muccioli C, et al. Cytomegalovirus antigenemia in acquired immunodeficiency syndrome patients with untreated cytomegalovirus retinitis. *Am J Ophthalmol* 1996;122:847-852.
- Boivin G, Handfield J, Murray G, et al. Quantitation of cytomegalovirus (CMV) DNA in leukocytes of human immunodeficiency virus-infected subjects with and without CMV disease by using PCR and the SHARP Signal Detection System. *J Clin Microbiol* 1997;35:525-526.
- Wetherill PE, Landry ML, Alcibes P, Friedland G. Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996;12:33-37.
- Salzberger B, Franzen C, Fatkenheuer G, et al. CMV-antigenemia in peripheral blood for the diagnosis of CMV disease in HIV-infected patients. *J Acquir Immune Defic Syndr Hum Retrovirol* 1996;11:365-369.
- Pellegrin I, Garrigue I, Binquet C, et al. Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients. *J Clin Microbiol* 1999;37:3124-3132.

Address correspondence to:

Naoyoshi Nagata, M.D.

Department of Gastroenterology and Hepatology

National Center for Global Health and Medicine

1-21-1, Toyama, Shinjuku-ku

Tokyo 162-8655

Japan

E-mail: nnagata\_ncgm@yahoo.co.jp

# Pharmacokinetics of Rifabutin in Japanese HIV-Infected Patients with or without Antiretroviral Therapy

Junko Tanuma<sup>1\*</sup>, Kazumi Sano<sup>2</sup>, Katsuji Teruya<sup>1</sup>, Koji Watanabe<sup>1</sup>, Takahiro Aoki<sup>1</sup>, Haruhito Honda<sup>1</sup>, Hirohisa Yazaki<sup>1</sup>, Kunihisa Tsukada<sup>1</sup>, Hiroyuki Gatanaga<sup>1</sup>, Yoshimi Kikuchi<sup>1</sup>, Shinichi Oka<sup>1</sup>

**1** AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan, **2** Department of Drug Metabolism and Disposition, Meiji Pharmaceutical University, Tokyo, Japan

## Abstract

**Objective:** Based on drug-drug interaction, dose reduction of rifabutin is recommended when co-administered with HIV protease inhibitors for human immunodeficiency virus (HIV)-associated mycobacterial infection. The aim of this study was to compare the pharmacokinetics of rifabutin administered at 300 mg/day alone to that at 150 mg every other day combined with lopinavir-ritonavir in Japanese patients with HIV/mycobacterium co-infection.

**Methods:** Plasma concentrations of rifabutin and its biologically active metabolite, 25-*O*-desacetyl rifabutin were measured in 16 cases with HIV-mycobacterial coinfection. Nine were treated with 300 mg/day rifabutin and 7 with 150 mg rifabutin every other day combined with lopinavir-ritonavir antiretroviral therapy (ART). Samples were collected at a median of 15 days (range, 5–63) of rifabutin use.

**Results:** The mean  $C_{max}$  and  $AUC_{0-24}$  of rifabutin in patients on rifabutin 150 mg every other day were 36% and 26% lower than on 300 mg/day rifabutin, while the mean  $C_{max}$  and  $AUC_{0-24}$  of 25-*O*-desacetyl rifabutin were 186% and 152% higher, respectively. The plasma concentrations of rifabutin plus its metabolite were similar between the groups within the first 24 hours, but it remained low during subsequent 24 to 48 hours under rifabutin 150 mg alternate day dosing.

**Conclusion:** Rifabutin dose of 150 mg every other day combined with lopinavir-ritonavir seems to be associated with lower exposure to rifabutin and its metabolite compared with rifabutin 300 mg/day alone in Japanese patients. Further studies are needed to establish the optimal rifabutin dose during ART. The results highlight the importance of monitoring rifabutin plasma concentration during ART.

**Trial registration:** UMIN-CTR (<http://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=search&action=input&language=E>) UMIN000001102

**Citation:** Tanuma J, Sano K, Teruya K, Watanabe K, Aoki T, et al. (2013) Pharmacokinetics of Rifabutin in Japanese HIV-Infected Patients with or without Antiretroviral Therapy. PLoS ONE 8(8): e70611. doi:10.1371/journal.pone.0070611

**Editor:** Omar Sued, Fundacion Huesped, Argentina

**Received:** February 26, 2013; **Accepted:** June 19, 2013; **Published:** August 5, 2013

**Copyright:** © 2013 Tanuma et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by the Health Labour Sciences Research Grant (#H18-AIDS-008 and #H21-AIDS-006) from the Ministry of Health, Labour and Welfare of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: [jtanuma@acc.ncgm.go.jp](mailto:jtanuma@acc.ncgm.go.jp)

## Introduction

Rifabutin is commonly used for human immunodeficiency virus (HIV)-associated mycobacterial infections, especially during combination antiretroviral therapy (cART) containing HIV protease inhibitors (PIs), since it is less likely to induce hepatic microsomal enzymes than rifampicin [1–4]. Conversely, rifabutin and its active metabolite, 25-*O*-desacetyl rifabutin, are substrates of CYP 3A4 and concomitant use of PIs can elevate blood concentrations of rifabutin and 25-*O*-desacetyl rifabutin [3–8]. Such rise can increase the risk of side effects such as anterior uveitis [2,9–12]. Thus, a lower dose of rifabutin has been recommended in patients treated with PIs.

The previously recommended dose of rifabutin in combination with ritonavir-boosted PI (PI/r) [13] of 150 mg every other day, was associated with low rifabutin plasma concentrations and increases rate of acquired rifamycin resistance [14–17].

Furthermore, the Tuberculosis Trials Consortium (TBTC)/US Public Health Service Study 23 [14] suggested that  $AUC_{0-24}$  of 4.5  $\mu\text{g}/\text{mL}$  is the cutoff value for risk of emergence of resistance to rifamycin. On the other hand, the combination of rifabutin at 150 mg thrice weekly with atazanavir-ritonavir provides exposure to rifabutin comparable to that of rifabutin 300 mg alone [11]. Thus, although 150 mg/day is the current recommended dose for rifabutin during PI/r-based cART [4], the optimal dose of rifabutin when used with a PI/r regimen remains to be established.

Ethnic differences, including body weight, renal clearance and various genetic factors like single nucleotide polymorphism (SNP), haplotype or DNA methylation [18,19], may alter the dose required to achieve a particular concentration of the drug in the circulation. Thus, pharmacokinetic studies involving different ethnic groups are needed to determine the recommended dose that take such factors into account. To our knowledge, there are no such pharmacokinetic studies for rifabutin use in Asians, who



are characterized by lower body weight compared with other ethnic groups. The present study was conducted to evaluate the pharmacokinetics of rifabutin in Japanese patients with HIV-1-related mycobacterial infection when used alone at 300 mg/day without cART and at 150 mg every other day when used in combination with lopinavir/ritonavir.

## Methods

### Ethics Statement

The study protocol was approved by the Ethics Committee of the National Center for Global Health and Medicine (NCGM-H20-580: approved on 7th February 2008). All participants provided their written informed consent before enrollment as indicated in the protocol.

The protocol for this study and supporting CONSORT checklist are available as supporting information; see File S1 for English translation of the protocol and File S2 for the Japanese original protocol and File S3 for CONSORT checklist.

### Study design

Consecutive patients with HIV-1-related mycobacterial infection who received rifabutin-containing therapy at the National Center for Global Health and Medicine, Tokyo, Japan, between February 2008 and March 2009, were eligible for the study. After their written informed consent was provided, clinical history, physical examinations and laboratory tests (e.g., blood chemistry and complete blood cell count) were carried out within one week prior to the pharmacokinetic study. Patients were excluded if they were over 20 years of age or if they had abnormal liver function tests [aspartate aminotransferase (AST), alanine aminotransferase (ALT) or total bilirubin (>3 times the upper limit of normal: ULN)], or severe renal dysfunction (creatinine clearance <30 ml/min), and in the case of female patients if they were pregnant or

breastfeeding. Rifabutin was administered while fasting at 300 mg/day and the dose was adjusted when used with cART as recommended by the treatment guideline at the time of the study [13]. Medications administered concomitantly or within 2 weeks before the first study day were recorded. To evaluate the impact of rifabutin plasma concentration on treatment efficacy and adverse events, participants were followed up for at least 2 years after stopping rifabutin. Any side effect noted during rifabutin use or within four weeks after stopping rifabutin, its association with rifabutin was assessed.

### Pharmacokinetic assays

Pharmacokinetic sampling commenced after 5 days of rifabutin-containing anti-mycobacterial therapy without (Group I) or with (Group II) cART. Sequential enrollment of a patient into both groups was accepted. Blood samples were collected just before rifabutin administration and then 0.5, 1, 2, 4, 6, 8 and 24 hours afterward. Patients of Group II treated with 150 mg of rifabutin every other day underwent additional sampling at 48 hours. The plasma concentrations of rifabutin and its major metabolite, 25-O-desacetyl rifabutin [20–23] were determined simultaneously by validated high-pressure liquid chromatography (HPLC). Blood samples were taken in heparin-containing tubes, placed on ice and centrifuged at 3000×g for 10 min. Then, the obtained plasma was deproteinized by using three times volume of methanol and centrifuged 15,000×g for 5 min, and the supernatant was used for assay. The HPLC standard for rifabutin and 25-O-desacetyl rifabutin were kindly provided by Pfizer Co. (Pfizer, Inc., NY). The HPLC system consisted of Agilent 1100 series (Agilent Technologies, Santa Clara, CA). Isocratic elution was performed using the Inertsil ODS-3 column (5 µm, 4.6 mm I.D. ×150 mm; GL Sciences Inc, Tokyo, Japan) with a guard column (5 µm, 4.6 mm I.D. ×10 mm; GL Sciences Inc). The UV detection wavelength was 280 nm. The mobile phase consisted of 9 mM

**Table 1.** Characteristics of study subjects.

	All (n = 16)	Group I (without cART, n = 9)	Group II (with cART, n = 7)	p value <sup>a</sup>
Male sex, n	16	9	7	
Age, median years (range)	36 (23–60)	36 (23–55)	35 (23–60)	0.53
Body weight, median kg (range)	57.3 (44–66)	58.0 (46–64)	56.5 (44–66)	0.98
Mycobacterium, multiple choice, n				
<i>M. tuberculosis</i>	13	7	6	1.00
<i>M. avium</i>	4	3	1	0.94
<i>M. kansasii</i>	1	0	1	0.85
CD4 count, median cells/mm <sup>3</sup> (range)	63 (2–164)	63 (2–164)	63 (19–135)	0.84
Plasma viral load, median log copies/ml (range)	4.97 (3.43–6.62)	4.98 (4.18–6.62)	4.95 (3.43–5.18)	0.10
AST, median IU/L (range)	29 (16–70)	25 (16–59)	30 (17–51)	0.65
ALT, median IU/L (range)	27 (13–70)	26 (23–70)	29 (19–70)	0.31
Time on rifabutin, median days (range)	15 (5–63)	7 (5–20)	29 (10–63)	0.017
Time on cART, median days (range)	14 (10–29)	–	14 (10–29)	–
Concomitant medications, n				
lopinavir-ritonavir	7	–	7	–
clarithromycin	3	2	1	1.00
fluconazole	1	0	1	0.85

<sup>a</sup>By Fisher's exact test for categorical data and Mann Whitney's U test for continuous variables.

cART, combination antiretroviral therapy; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IU, international unit.

doi:10.1371/journal.pone.0070611.t001

phosphate buffer (pH 6.8)-acetonitrile (30:70, v/v). The flow-rate was set at 1.0 ml/min and all separations were performed at 30°C in column oven.

### Statistical and pharmacokinetic analyses

The area under the curve (AUC) was calculated using non-compartmental techniques (WinNonlin, ver. 5, Pharsight Corp., Mountain View, CA) based on the obtained values (AUC 0–24 h for all, AUC 0–48 h for Group II). The maximum plasma concentration ( $C_{max}$ ) and time of  $C_{max}$  ( $T_{max}$ ) were determined directly from the data.


Statistical analyses were performed using SPSS software package for Windows, version 17.0J (SPSS Japan Inc, Tokyo). Differences between groups were determined by using the Fisher's exact test for categorical data and the Mann Whitney's test for continuous variables. For all statistical analyses, differences were considered significant if the p value was less than 0.05.

## Results

### Patient characteristics

A total of 15 patients were enrolled in the study and 5 of 15 participated in both Group I and II. In total, twenty sampling was

done for rifabutin pharmacokinetic analysis; 11 in Group I and 9 in Group II. Data from two sampling in Group I and 2 in Group II were excluded from the analysis because samples at 24-hour were unavailable or sampling was conducted earlier than 5 days of rifabutin use. As a result, data from 9 sampling in Group I and 7 sampling in Group II were used for analysis. The baseline characteristics of the 16 sampling cases are summarized in Table 1. All 7 patients of Group II were being treated with lopinavir/ritonavir as their cART, and thus rifabutin was administered at 150 mg every other day based on the guidelines at the time of the study [13]. Two cases of Group I and 1 of Group II were being treated with clarithromycin (CAM) [20] for systemic mycobacterial infection caused by *M. avium* or *M. intracellulare* (*M. avium* Complex: MAC). Five patients of Group I, in whom ART had been delayed several weeks after anti-mycobacterial therapy to prevent the immune reconstitution inflammatory syndrome (IRIS), were later enrolled in the study as patients of Group II (Figure 1). Accordingly, the median time of rifabutin use was longer in Group II than in Group I. There was no significant difference between the groups with regard to gender, age, body weight, CD4 counts, HIV-RNA load, type of mycobacteria and concomitant use of clarithromycin or fluconazole. All were Japanese and the median body weight was 57.3 kg. All patients completed their anti-



**Figure 1. Flow chart of participants through the study.** PK, pharmacokinetic; ART, antiretroviral therapy.  
doi:10.1371/journal.pone.0070611.g001

**Table 2.** Pharmacokinetic parameters for rifabutin and 25-*O*-desacetyl rifabutin.

	Group I (without combination antiretroviral therapy, n = 9)		Group II (with combination antiretroviral therapy, n = 7)		P value <sup>a</sup>
	Median (range)	Mean (90% CI)	Median (range)	Mean (90% CI)	
<b>Rifabutin</b>					
C <sub>max</sub> (µg/mL)	0.46 (0.15–0.86)	0.44 (0.39–0.49)	0.28 (0.10–0.44)	0.29 (0.25–0.33)	0.10
AUC <sub>0–24</sub> (µg h/mL)	2.79 (1.32–15.7)	4.86 (3.83–5.90)	3.00 (1.13–5.43)	3.38 (2.92–3.84)	0.38
AUC <sub>0–48</sub> (µg h/mL) <sup>b</sup>	5.59 (2.63–31.3)	9.71 (7.62–511.8)	4.21 (1.76–6.90)	4.58 (3.38–5.78)	0.32
T <sub>max</sub> (h)	2.0 (2.0–4.0)	2.9 (2.6–3.1)	6.0 (2.0–12.0)	4.8 (4.1–5.1)	0.03
<b>25-<i>O</i>-desacetyl rifabutin</b>					
C <sub>max</sub> (µg/mL)	0.00 (0.00–0.30)	0.05 (0.03–0.08)	0.13 (0.05–0.23)	0.14 (0.12–0.16)	0.05
AUC <sub>0–24</sub> (µg h/mL)	0.00 (0.00–3.69)	0.82 (0.45–1.20)	1.52 (0.44–3.64)	2.07 (1.62–2.52)	0.12
AUC <sub>0–48</sub> (µg h/mL) <sup>b</sup>	0.00 (0.00–7.38)	1.64 (0.89–2.39)	5.93 (0.44–7.21)	4.32 (3.27–5.38)	0.15
T <sub>max</sub> (h)	6.0 (2.0–8.0)	5.3 (4.6–6.0)	6.0 (2.0–12.0)	5.7 (4.6–6.9)	0.87
<b>Rifabutin plus 25-<i>O</i>-desacetyl rifabutin</b>					
C <sub>max</sub> (µg/mL)	0.47 (0.15–0.99)	0.49 (0.40–0.52)	0.42 (0.16–0.56)	0.39 (0.34–0.44)	0.54
AUC <sub>0–24</sub> (µg h/mL)	3.36 (1.32–19.3)	5.49 (4.18–6.76)	6.23 (1.57–7.92)	5.27 (4.48–6.07)	0.93
AUC <sub>0–48</sub> (µg h/mL) <sup>b</sup>	6.72 (2.63–38.7)	10.9 (8.35–13.5)	6.80 (2.20–14.1)	7.95 (6.40–9.49)	0.46

<sup>a</sup>By the Mann Whitney's *U* test.

<sup>b</sup>In Group I, AUC<sub>24–48</sub> is assumed the same as AUC<sub>0–24</sub> and AUC<sub>0–48</sub> is calculated as double of AUC<sub>0–24</sub> for comparison with Group II.

C<sub>max</sub>, maximum plasma concentration; AUC, area under the curve; T<sub>max</sub>, time of C<sub>max</sub>; CI, confidence interval.

doi:10.1371/journal.pone.0070611.t002

mycobacterial treatment with clinical resolution of mycobacterial infections. None of the participants had treatment failure or relapse within more than 3 years of observation. Worsening of intra-abdominal lymphadenitis was observed in one patient with systemic *M. avium* infection at 8 months after stopping the 2-year rifabutin-containing anti-mycobacterial therapy, which excluded treatment failure or relapse. All patients confirmed complete adherence to anti-mycobacterial therapy and cART.

### Pharmacokinetic parameters of rifabutin and its 25-*O*-desacetyl metabolite

The pharmacokinetic parameters of rifabutin and 25-*O*-desacetyl rifabutin are summarized in Table 2 and their mean plasma concentration-time data of 48 hours are illustrated in Figure 2A and 2B. For calculation of AUC<sub>0–48</sub>, the data from 24 to 48 hours in Group I was assumed to be the same as that for 0–24 hours because rifabutin was administered once a day at the same dosage. As shown in Table 2, the mean values of C<sub>max</sub> and AUC<sub>0–24</sub> of rifabutin were 36% and 26% lower in Group II than in Group I, while the mean values of C<sub>max</sub> and AUC<sub>0–24</sub> of 25-*O*-desacetyl rifabutin were 186% and 152% higher in Group II than in Group I. However, the differences in the above values between the two groups were not statistically different. The low rifabutin concentration and high metabolite concentration in Group II may reflect the induction of rifabutin metabolism due to the longer duration of rifabutin use. Since 25-*O*-desacetyl rifabutin is microbiologically active against mycobacterium, total rifabutin activity might include rifabutin plus this metabolite. Figure 2C illustrates the mean plasma concentration of rifabutin plus the metabolite over time. Patients of Groups I and II had similar plasma concentrations of rifabutin plus the metabolite within the first 24 hours. However, the level of rifabutin plus the metabolite during the subsequent 24–48 hours was considerably lower in Group II than in Group I (dotted line in Figure 2C: Group I during 0–24 hours), whereas the AUC<sub>0–48</sub> was not statistically

different between the groups. Notably, 6 (67%) cases of Group I and 5 (71%) of Group II failed to achieve the AUC<sub>0–24</sub> value suggested as risk for emergence of rifamycin-resistant *M. tuberculosis* [14] (4.5 µg h/mL). Neither C<sub>max</sub> nor AUC<sub>0–24</sub> of rifabutin and 25-*O*-desacetyl rifabutin were associated with age, body weight, body mass index, or CD4 count.


### Rifabutin-associated side effects

Of the 15 participants, three patients developed side effects possibly related to rifabutin during the observational period; two of Group I developed skin rash and the other of Group II developed grade 2 rise in liver enzymes (ALT or AST 2.6–5.0 times of ULN). The skin rash appeared on day 11 of rifabutin-containing regimen in one patient and on day 28 in the other, and was resolved in both patients within several days after withdrawal of rifabutin. The rise in liver enzymes was detected after two months of rifabutin-containing regimen in combination with cART, and improved soon after discontinuation of rifabutin. Notably, the median CD4 counts in the three patients with rifabutin toxicity were significantly lower than in patients without rifabutin toxicity (12 vs 76, cells/mm<sup>3</sup>, *p* = 0.028). However, rifabutin toxicity did not correlate with rifabutin AUC<sub>0–24</sub>, C<sub>max</sub>, or the concurrent use of cART (rifabutin AUC<sub>0–24</sub>: *p* = 0.37, rifabutin C<sub>max</sub>: *p* = 0.86, cART use: *p* = 0.21).

### Discussion

In the present study, a low dose of rifabutin (150 mg every other day), in combination with lopinavir/ritonavir-containing cART, yielded comparable AUC<sub>0–24</sub> of rifabutin and 25-*O*-desacetyl rifabutin to the commonly used dose of rifabutin of 300 mg/day. The advantage of the low-dose rifabutin included lower exposure to rifabutin and metabolite during the subsequent 24 to 48 hours in Japanese patients with HIV-mycobacteria co-infection. Since many participants started their cART after at least 1 month of





**Figure 2. Mean plasma concentrations-versus-time plots of rifabutin (A), 25-O-desacetyl rifabutin (B), and rifabutin plus 25-O-desacetyl rifabutin (C).** Nine patients of Group I received 300 mg of rifabutin and 7 patients of Group II received 150 mg of rifabutin every other day with lopinavir/ritonavir-containing antiretroviral therapy. Solid circles: Group I, open circles: Group II. Data are mean  $\pm$  1 standard errors. Dotted line in Figure C represents data of Group I during 0–24 hour for reference. RBT, rifabutin; PI/r, ritonavir-boosted protease inhibitor.

doi:10.1371/journal.pone.0070611.g002

anti-mycobacterial therapy in order to avoid deterioration by immune-reconstitution syndrome, the metabolism of rifabutin was induced upon the commencement of cART. This led to lower rifabutin concentration and higher 25-O-desacetyl rifabutin concentration in Group II but provided similar concentrations of rifabutin plus its active metabolite. However, on the day without medication, plasma concentrations of rifabutin and its active metabolite were lower in Group II, which were less than the susceptibility breakpoint level for *M. tuberculosis* proposed by others [20]. This suggests increased risk of emergence of rifamycin-resistant *M. tuberculosis* during the day without medication under low-dose rifabutin therapy, and that the currently recommended dosage 150 mg daily with PI/r is reasonable to this population as well. In this regard, Zhang et al. [11] reported that treatment with 150 mg/day rifabutin with atazanavir-ritonavir resulted in high risk of severe neutropenia. Furthermore, their post-hoc simulation showed that rifabutin 150 mg thrice weekly with atazanavir-ritonavir provided a comparable exposure to rifabutin compared with rifabutin 300 mg daily. Considering the risk of rifamycin-resistance and rifabutin toxicity, monitoring of rifabutin plasma

concentration should be considered until the optimal rifabutin dosing during PI/r-based cART is fully established.

Although none of the patients showed treatment failure or relapse in this study, the rifabutin AUC<sub>0-24</sub> observed in the study was in general close to the low end of the value reported in previous studies [7,14] and many participants [6 (67%) of Group I and 5 (71%) of Group II] failed to achieve AUC<sub>0-24</sub> 4.5 µg/h/mL, the cutoff value suggested as risk for emergence of rifamycin-resistant *M. tuberculosis* [14]. One of the reasons for this discordant result might be the limitation of our study of small sample size involving several MAC and *M. kansasii* infections. Since acquisition of rifamycin-resistance *M. tuberculosis* was not frequent enough in this study group, it was difficult to evaluate the association with rifabutin pharmacokinetics and emergence of rifamycin-resistance. Other reasons may be the biological characteristics of rifabutin. Rifabutin has long postantibiotic effect against *M. tuberculosis* and MAC [20], shows extensive distribution in various tissues [21,22], and readily penetrates cell membranes of leucocytes [21,22]. These characteristics and their variations among patients can considerably influence the outcome of rifabutin-containing anti-mycobacterial therapy and therefore might be one of the explanations of favorable efficacy despite lower plasma concentrations of rifabutin in our study. Another limitation of this study is that plasma concentration of isoniazid was not measured, although low isoniazid plasma concentration is known to be independently related to treatment failure of HIV/TB co-infection [24]. Additionally, although there was no difference in rifabutin concentration among the patients with or without use of clarithromycin or fluconazole, those drugs can increase the rifabutin AUC and possibly affect the results. Since our study was enrolling patients with heterogeneous backgrounds in the real clinical setting, such as timing of sampling or different combination of anti-mycobacterial drugs, it was difficult to completely eliminate those impacts from the analysis. These conditions should be taken into account in the assessment of treatment outcome and associated factors in this study.

Among 15 study participants, 3 patients developed side effects related to rifabutin therapy, including skin rash and rise in liver enzymes. Notably, their CD4 counts were lower than those who did not show rifabutin toxicity, although rifabutin plasma concentrations and the concurrent use of cART were similar in the two groups. This is the first report implicating low CD4 count as a risk factor for rifabutin-related side effects. However, like other side effects of rifabutin, such as uveitis and leukocytopenia, which have been reported to be related to high-dose rifabutin or high rifabutin plasma concentrations [9–12], careful assessment involving larger population samples are needed to evaluate the association between high plasma concentrations of rifabutin and the related skin rash and hepatotoxicity.

In conclusion, in Japanese patients with HIV-mycobacteria co-infection, the plasma concentrations of rifabutin and active metabolite within the first 24 hours of treatment with low-dose rifabutin (150 mg every other day) combined with lopinavir-ritonavir, were similar to those encountered with 300 mg/day rifabutin alone. However, these concentrations decreased on the day without medication. Our findings could help determine the optimal dose of rifabutin during cART. Further studies are needed to establish the optimal dose of rifabutin during cART. Monitoring of rifabutin plasma concentration should be considered in patients with HIV-mycobacteria co-infection.

## Supporting Information

**Protocol S1 Summary in English.** English translation of the protocol Summary. (DOCX)

**Protocol S1 Protocol and IC form in Japanese.** The full version of the study protocol and the informed consent form in Japanese. (PDF)

**CONSORT Checklist S2.** (DOC)

## References

- American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. (2003) AmericanThoracicSociety/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. *Am J Respir Crit Care Med* 6: 603–662.
- Pfizer, Inc. *Mycobutin (rifabutin) prescribing information*. Pfizer, Inc., New York, NY. Available: [http://www.pfizer.com/files/products/uspi\\_mycobutin.pdf](http://www.pfizer.com/files/products/uspi_mycobutin.pdf). Accessed 2012 August 21.
- Centers for Disease Control and Prevention. (2009) Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. *MMWR* 58: 1–207.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available: <http://aidsinfo.nih.gov/contentfiles/vguidelines/AdultandAdolescentGL.pdf>. Accessed 2012 August 21.
- Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, et al. (2004) Indinavir and rifabutin drug interactions in healthy volunteers. *J Clin Pharmacol* 44: 305–313.
- Ford SL, Chen YC, Lou Y, Borland J, Min SS, et al. (2008) Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. *Antimicrob Agents Chemother* 52: 534–538.
- Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, et al. (2009) Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. *Clin Infect Dis* 49: 1305–1311.
- Zhang X, Fettner S, Zwanziger E, Rowell L, Salgo M, et al. (2011) Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects. *Antimicrob Agents Chemother* 55: 680–687.
- Centers for Disease Control and Prevention. (1994) Uveitis associated with rifabutin therapy. *MMWR* 43: 658.
- Shafran SD, Singer J, Zarowny DP, Deschênes J, Phillips P, et al. (1998) Determinants of rifabutin-associated uveitis in patients treated with rifabutin, clarithromycin, and ethambutol for *Mycobacterium avium* complex bacteremia: a multivariate analysis. *Canadian HIV Trials Network Protocol 010 Study Group. J Infect Dis* 177: 252–255.
- Zhang J, Zhu L, Stonier M, Coumbis J, Xu X, et al. (2011) Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. *J Antimicrob Chemother* 66: 2075–2082.
- Sekar V, Lavreys L, Van de Castele T, Berckmans C, Spinosa-Guzman S, et al. (2010) Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. *Antimicrob Agents Chemother* 54: 4440–4445.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. (2008) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3: 1–139. Available: <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. Accessed 2012 August 21.
- Weiner M, Benator D, Burman W, Peloquin CA, Khan A, et al. (2005) Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. *Clin Infect Dis* 40: 1481–1491.
- Jenny-Avital ER, Joseph K (2009) Rifamycin-resistant *Mycobacterium tuberculosis* in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. *Clin Infect Dis* 48: 1471–1474.
- Li J, Munsiff SS, Driver CR, Sackoff J (2005) Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997–2000. *Clin Infect Dis* 41: 83–91.
- Khachi H, O'Connell R, Ladenheim D, Orkin C, et al. (2009) Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. *J Antimicrob Chemother* 64: 871–873.
- Gomez A, Ingelman-Sundberg M (2009) Pharmacogenetics: its role in interindividual differences in drug response. *Clin Pharmacol Ther* 85: 426–430.
- Lee IS, Kim D (2011) Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. *Arch Pharm Res* 34: 1799–1816.
- Kunin GM (1996) Antimicrobial activity of rifabutin. *Clin Infect Dis* 22: S3–13.
- Skinner MH, Hsieh M, Torseth J, Pauloin D, Bhatia G, et al. (1989) Pharmacokinetics of rifabutin. *Antimicrob Agents Chemother* 33: 1237–1241.
- Blaschke TF, Skinner MH (1996) The clinical pharmacokinetics of rifabutin. *Clin Infect Dis* 22: S15–21.
- Strolin Benedetti M, Efthymiopoulos C, Sassella D, Moro E, Repetto M (1990) Autoinduction of rifabutin metabolism in man. *Xenobiotica* 20: 1113–1119.
- Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, et al. (2003) Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. *Tuberculosis Trials Consortium. Am J Respir Crit Care Med* 167: 1341–1347.

## Acknowledgments

We thank all the staff of the AIDS Clinical Center for the care of patients.

## Author Contributions

Conceived and designed the experiments: JT. Performed the experiments: JT KS. Analyzed the data: JT. Contributed reagents/materials/analysis tools: JT KS. Wrote the paper: JT. Technical advice: YK. Patients' recruitment: KW TA HH HY K. Tsukada. Technical advice: K. Teruya HG SO.

# Preemptive Therapy Prevents Cytomegalovirus End-Organ Disease in Treatment-Naïve Patients with Advanced HIV-1 Infection in the HAART Era

Daisuke Mizushima<sup>1,2</sup>, Takeshi Nishijima<sup>1,2</sup>, Hiroyuki Gatanaga<sup>1,2\*</sup>, Kunihisa Tsukada<sup>1</sup>, Katsuji Teruya<sup>1</sup>, Yoshimi Kikuchi<sup>1</sup>, Shinichi Oka<sup>1,2</sup>

<sup>1</sup> AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan, <sup>2</sup> Center for AIDS Research, Kumamoto University, Kumamoto, Japan

## Abstract

**Background:** The efficacy of preemptive therapy against cytomegalovirus (CMV) infection remains unknown in treatment-naïve patients with advanced HIV-1 infection in the HAART era.

**Methods:** The subjects of this single-center observation study were 126 treatment-naïve HIV-1 infected patients with positive CMV viremia between January 1, 2000 and December 31, 2006. Inclusion criteria were age more than 17 years, CD4 count less than 100/μl, plasma CMV DNA positive, never having received antiretroviral therapy (ART) and no CMV end-organ disease (EOD) at first visit. The incidence of CMV-EOD was compared in patients with and without preemptive therapy against CMV-EOD. The effects of the CMV preemptive therapy were estimated in uni- and multivariate Cox hazards models.

**Results:** CMV-EOD was diagnosed in 30 of the 96 patients of the non-preemptive therapy group (31%, 230.3 per 1000 person-years), compared with 3 of the 30 patients of the preemptive therapy group (10%, 60.9 per 1000 person-years). Univariate (HR = 0.286; 95%CI, 0.087–0.939;  $p = 0.039$ ) and multivariate (adjusted HR = 0.170; 95%CI, 0.049–0.602;  $p = 0.005$ ) analyses confirmed that CMV-EOD is significantly prevented by CMV preemptive therapy. Multivariate analysis showed that plasma CMV DNA level correlated significantly with CMV-EOD (per log<sub>10</sub>/ml, adjusted HR = 1.941; 95%CI, 1.266–2.975;  $p = 0.002$ ). Among the 30 patients on preemptive therapy, 7 (23.3%) developed grade 3–4 leukopenia. The mortality rate was not significantly different between the two groups ( $p = 0.193$ , Log-rank test).

**Conclusions:** The results indicate that preemptive therapy lowers the incidence of CMV-EOD by almost 25%. Preemptive therapy for treatment-naïve patients with CMV viremia is effective, although monitoring of potential treatment-related side effects is required.

**Citation:** Mizushima D, Nishijima T, Gatanaga H, Tsukada K, Teruya K, et al. (2013) Preemptive Therapy Prevents Cytomegalovirus End-Organ Disease in Treatment-Naïve Patients with Advanced HIV-1 Infection in the HAART Era. PLoS ONE 8(5): e65348. doi:10.1371/journal.pone.0065348

**Editor:** Michael Nevels, University of Regensburg, Germany

**Received:** January 7, 2013; **Accepted:** April 24, 2013; **Published:** May 28, 2013

**Copyright:** © 2013 Mizushima et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by a Grant for National Center for Global Health and Medicine (23-114). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

\* E-mail: hingatana@acc.ncgm.go.jp

## Introduction

Although the incidence of new cases of cytomegalovirus (CMV) end-organ disease (EOD) has decreased by 75%–80% with the advent of antiretroviral therapy (ART) and is currently estimated to be <6 cases per 100 person-years [1], CMV-EOD is still one of the major debilitating diseases among patients with advanced HIV infection.

CMV preemptive therapy is commonly used for patients scheduled for hematopoietic cell transplantation and solid organ transplantation, with clinical evidence of efficacy [2–6], however, it is not generally recommended in HIV patients [7] because of concerns regarding cost-effectiveness, risk of developing CMV resistance, side effect and the lack of a proven survival benefit [8]. A prospective trial in cooperation with Roche company to evaluate the efficacy of preemptive therapy in the pre-HAART (highly active ART) era showed significant preventive effect of oral

ganciclovir (GCV) [9]. However; other studies conducted in both pre-HAART and HAART eras showed no significant effect [10,11]. However, the above studies included patients who had previously received ART. Therefore, the efficacy of preemptive therapy against CMV infection remains unknown in treatment-naïve patients with advanced HIV-1 infection in the HAART era.

We retrospectively compared the incidence of CMV-EOD in a cohort of ART-naïve adult patients with advanced HIV infection (low CD4 count and plasma CMV-DNA-positive). One group of these patients had received CMV preemptive therapy, while the other had not received such therapy.

## Methods

### Ethics Statement

The study was approved by the Human Research Ethics Committee of National Center for Global Health and Medicine,

Tokyo. All patients included in this study provided a written informed consent for their clinical and laboratory data to be used and published for research purposes. This study has been conducted according to the principles expressed in the Declaration of Helsinki.

### Study design

We performed a retrospective, single-center cohort study to elucidate the effectiveness of preemptive CMV treatment in HIV-infected patients with positive CMV viral load in the prevention of CMV-EOD. The study was conducted at the National Center for Global Health and Medicine, Tokyo, one of the largest clinics for patients with HIV infection in Japan, with more than 2,700 registered patients as of December 2006. The study population comprised treatment-naïve HIV infected patients aged more than 17 years, with CD4 count less than 100/ $\mu$ l and positive plasma CMV DNA viral load, who presented for the first time at our hospital between January 1, 2000 and December 31, 2006. Those with CMV-EOD at presentation and those with <3 months of follow-up were excluded. The follow-up period was 2 years from the initial visit.

### Definition of CMV-EOD and CMV preemptive therapy

CMV-EOD was diagnosed according to standardized ACTG criteria (see Table S1) [11]. CMV retinitis was routinely screened for by dilated indirect ophthalmoscopy at both the first visit to the hospital and a few months after the commencement of ART. Other evaluations, such as endoscopy and bronchoscopy, were carried out in response to the symptoms and clinical condition. The diagnosis of CMV-EOD was established by at least two experts from our hospital.

CMV preemptive therapy was prescribed based on the clinician's assessment. CMV preemptive therapy was provided at our institution for patients with plasma CMV DNA of >5000 copies/ml. For patients with plasma CMV DNA of >3000 but less than 5000 copies/ml, the decision to initiate preemptive therapy was left to the attending physician, taking into consideration the overall clinical condition, such as subsequent rise in plasma CMV DNA and/or use of immunosuppressants, such as steroids and chemotherapeutic agents. Ganciclovir (GCV) and valganciclovir (VGCV) were the most commonly used agents, followed by foscarnet (FOS). The choice of induction (intravenous GCV 5 mg/kg every 12 hours, oral VGCV900 mg twice a day or intravenous FOS 90 mg/kg every 12 hours) or maintenance dose (intravenous GCV 5 mg/kg every 24 hours, oral VGCV 900 mg a day or intravenous FOS 90 mg/kg every 24 hours) was based on the clinical condition, such as the level of plasma CMV DNA or state of immunosuppression. The duration of therapy varied across individuals. CMV preemptive therapy was defined as at least a 7-day treatment with agents effective against CMV. The normal course of CMV preemptive therapy was 2 weeks of GCV induction dose followed by VGCV or GCV maintenance dose until plasma CMV DNA became negative. Patients were retreated based on clinicians' decision under some conditions with high risks for CMV-EOD as described above, if plasma CMV DNA became positive again after preemptive therapy.

### Measurements

Plasma CMV DNA was measured using real-time PCR with a lower limit of detection of 200 copies/mL (CMV geniQ, Bio Medical Laboratory, Inc., Tokyo, Japan). Plasma CMV DNA was measured routinely at the first visit in patients with CD4 count of <100/ $\mu$ l, and re-examined every week or monthly, according to

the level of plasma CMV DNA viral load or immune status and at the discretion of the attending physician.

In this study, the primary exposure variable was CMV preemptive therapy over no CMV preemptive therapy. The potential risk factors for CMV-EOD were determined based on previous studies [12–18], and included basic demographics and laboratory data, including age, sex, CD4 cell count, HIV viral load, plasma CMV DNA, and presence or absence of other medical conditions (concurrent use of steroids, concurrent chemotherapy and concurrent AIDS-defining diseases). For each patient, data on or closest to the day of the first visit to our hospital were retrieved for analysis.

### Statistical analysis

Categorical and continuous baseline demographics and laboratory data were analyzed using Pearson's chi-square test and Student's t-test, respectively. The time from the first visit to our hospital to the development of CMV-EOD was analyzed by the Kaplan Meier method for patients on CMV preemptive therapy and no CMV preemptive therapy, and the log-rank test was used to determine the statistical significance. Censored cases represented those who died, dropped out, or were referred to other facilities before the end of follow-up period. The Cox proportional hazards regression analysis was used to estimate the impact of CMV preemptive therapy on the incidence of CMV-EOD. The impact of basic demographics, baseline laboratory data, and other medical conditions was also estimated with univariate Cox proportional hazards regression.

To estimate the unbiased prognostic impact of CMV preemptive therapy, we used three models based on multivariate Cox proportional hazards regression analysis. Model 1 was the aforementioned univariate analysis for CMV preemptive therapy. Model 2 included age and sex, plus Model 1, in order to adjust for basic characteristics. In Model 3, we added variables with significant relation to CMV-EOD by univariate analysis or assumed as risk factor(s) for CMV-EOD in the literature [12–20] (e.g., CD4 count per 1/ $\mu$ l decrement, HIV viral load per log<sub>10</sub>/ml, CMVDNA viral load per log<sub>10</sub>/ml, concurrent steroid use, concurrent chemotherapy and concurrent AIDS defining disease). Statistical significance was set at two-sided *p* values <0.05. We used hazard ratios (HRs) and 95% confidence intervals (95% CIs) to estimate the impact of each variable on CMV-EOD. All statistical analyses were performed with The Statistical Package for Social Sciences ver. 17.0 (SPSS, Chicago, IL).

### Results

Of the 199 HIV-infected patients with CD4 count <100/ $\mu$ l and positive plasma CMV DNA viral load referred to our hospital between January 1, 2000 and December 31, 2006, 126 patients were recruited in the study. Of these, 96 patients received CMV preemptive therapy while 30 did not (Figure 1). Table 1 lists the demographics, laboratory data, and medical conditions of the study population at baseline. The majority of the study population were males, East Asians, and relatively young (median: 42 years). There were no differences in baseline CD4 count (*p* = 0.595) and HIV viral load (*p* = 0.628) between the two groups. Patients of the CMV preemptive therapy group had higher plasma CMV DNA viral load (*p* < 0.001), more likely to have developed AIDS defining diseases (*p* = 0.042), and tended to have been treated concurrently with steroids (*p* = 0.009), compared with the non-CMV preemptive group. There were no significant differences in the use of chemotherapy (*p* = 1.000) and in time to initiation of ART since study entry (*p* = 0.393, Table 1) between the two groups.